ClinicalTrials.gg
CompletedNCT01249118Updated May 10, 2017Results posted

An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)

A Phase 1 interventional study of GDC-0973 IV Infusion and GDC-0973 Oral Capsules in Healthy Volunteers, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of Part 1 of this study is to evaluate the safety and tolerability of the intravenous (IV) dose of GDC-0973. The primary objectives of Part 2 of this study are to evaluate the absolute bioavailability of GDC-0973 and to evaluate the pharmacokinetic (PK) of GDC-0973 following IV and oral administration. The secondary objective of Part 2 of this study is to evaluate the safety of GDC-0973 administered orally and intravenously.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Within range 18.5 to 29.9 kilograms per square meter (kg/m\^2)
  • In good health, determined by no findings from medical history, 12-lead (ECG), and vital signs
  • Clinical laboratory evaluations within the reference range for the test laboratory
  • Negative test for selected drugs of abuse at Screening and at each Check-in
  • Negative hepatitis panel and anti- virus and negative (HIV) antibody screens
  • Healthy males and females of non- or who agree to use effective

Exclusion criteria

Exclusion Criteria

  • Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy, hernia repair, and cholecystectomy will be allowed
  • History or presence of an abnormal
  • History of alcoholism or drug addiction prior to period 1 check-in
  • Use of any tobacco-containing or nicotine-containing products prior to period 1 check-in
  • Participation in any other study drug trial in which receipt of an investigational study drug occurred within 28 days or 5 half-lives, whichever is longer, prior to period 1 check-in
  • Use of any prescription medications/products, including proton pump inhibitors, within 14 days prior to period 1 check-in
  • Poor peripheral venous access
  • Any acute or chronic condition that would limit the participants ability to complete and/or participate in this clinical study
  • Female participant is pregnant, lactating, or breastfeeding
  • Predisposing factors to retinal vein occlusion (RVO)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules

    Participants will receive single dose of GDC-0973 2 milligrams (mg) IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.

    Drug: GDC-0973 IV Infusion · Drug: GDC-0973 Oral Capsules

  • Experimental
    Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules

    Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.

    Drug: GDC-0973 IV Infusion · Drug: GDC-0973 Oral Capsules

  • Experimental
    Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion

    Participants will receive single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in first intervention period followed by single dose of GDC-0973 2 mg IV infusion in second intervention period. The washout period between each period will be a minimum of 10 days.

    Drug: GDC-0973 IV Infusion · Drug: GDC-0973 Oral Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of IV and Oral GDC-0973

    Time frame: Part 2: 0 hours (Hrs) (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  2. Dose Normalized Cmax [Cmax(dn)] of IV and Oral GDC-0973

    Cmax(dn) is Cmax divided by dose.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  3. Minimum Observed Plasma Trough Concentration (Cmin) of IV and Oral GDC-0973

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax) of IV and Oral GDC-0973

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  5. Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of IV and Oral GDC-0973

    AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  6. Dose Normalized AUC (0-t) [AUC (0-t)dn] of IV and Oral GDC-0973

    AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t). AUC (0-t)dn is AUC (0-t) divided by dose.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  7. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of IV and Oral GDC-0973

    AUC (0 - ∞)= Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  8. Dose Normalized AUC (0 - ∞) [AUC (0 - ∞)dn] of IV and Oral GDC-0973

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞)dn is AUC(0 - ∞) divided by dose.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  9. Plasma Decay Half-Life (t1/2) of IV and Oral GDC-0973

    t1/2 is the time measured for the plasma concentration of GDC-0973 to decrease by one half.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  10. Systemic Clearance (CL) of IV GDC-0973

    CL is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  11. Apparent Oral Clearance (CL/F) of Oral GDC-0973

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modelling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  12. Volume of Distribution at Steady State (Vss) of IV GDC-0973

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vss is the apparent volume of distribution at steady-state.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose of Day 1

  13. Apparent Volume of Distribution (Vz/F) of Oral GDC-0973

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F is influenced by the fraction absorbed.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  14. Absolute Oral Bioavailability (F) of GDC-0973

    Absolute oral bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose. F = \[AUC (0-∞), oral multiplied by Dose IV\] divided by \[AUC (0-∞), IV multiplied by Dose oral\]. Absolute oral bioavailability is determined for drugs which are administered orally. IV dose is 100% in systemic circulation (dosed directly) and hence no estimation is required.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  15. Mean Absorption Time (MAT)

    MAT is mean time required for the drug to reach the central compartment. MAT was estimated from the mean resident time (MRT) from oral and IV administration. MAT was calculated as MRT last of oral dose minus MRT last of IV dose. MAT is analyzed when drug is administered orally (only for non-IV routes of administration).

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1

  16. Amount of Drug Excreted in the Urine (Aeu) of IV and Oral GDC-0973

    The cumulative amount of drug excreted in urine over the entire collection interval of 96 hrs was calculated by adding the Aeu of the intervals 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 hrs where Aeu was calculated by multiplying the urine volume within the collection interval by the associated drug concentration.

    Time frame: Part 2: 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 Hrs post-dose on Day 1

  17. Renal Clearance (CLR) of IV and Oral GDC-0973

    CLR was calculated as Aeu divided by AUC (0 - ∞), where Aeu was amount of drug excreted in urine from time 0 to 96 hrs post-dose and AUC(0 - ∞) was area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity hrs post-dose.

    Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1 for plasma; 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 Hrs post-dose for urine

  18. Percent of GDC-0973 Excreted in the Urine (% Excreted) for IV and Oral GDC-0973

    % Excreted is the mean percentage of dose recovery in urine and calculated as: (Aeu divided by dose) multiplied by 100, where Aeu was amount of drug excreted in urine from time 0 to 96 hrs post-dose.

    Time frame: Part 2: 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 Hrs post-dose

07

Results

Posted Feb 6, 2017

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestonePart 1: GDC-0973 IV Infusion First, Then GDC-0973 CapsulesPart 2: GDC-0973 IV Infusion First, Then GDC-0973 CapsulesPart 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion
Started265
Completed265
Not completed000
First Washout Period
Participant flow — First Washout Period
MilestonePart 1: GDC-0973 IV Infusion First, Then GDC-0973 CapsulesPart 2: GDC-0973 IV Infusion First, Then GDC-0973 CapsulesPart 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion
Started265
Completed255
Not completed010
Withdrew: Physician decision010
Second Intervention Period
Participant flow — Second Intervention Period
MilestonePart 1: GDC-0973 IV Infusion First, Then GDC-0973 CapsulesPart 2: GDC-0973 IV Infusion First, Then GDC-0973 CapsulesPart 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion
Started255
Completed255
Not completed000
Second Washout Period
Participant flow — Second Washout Period
MilestonePart 1: GDC-0973 IV Infusion First, Then GDC-0973 CapsulesPart 2: GDC-0973 IV Infusion First, Then GDC-0973 CapsulesPart 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion
Started255
Completed255
Not completed000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of IV and Oral GDC-0973
Time frame:
Part 2: 0 hours (Hrs) (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of IV and Oral GDC-0973
nanograms per milliliter (ng/mL)GDC-0973 2 mg IVGDC-0973 20 mg Oral
Maximum Observed Plasma Concentration (Cmax) of IV and Oral GDC-097320.5 ± 35.615.2 ± 26.4
PrimaryDose Normalized Cmax [Cmax(dn)] of IV and Oral GDC-0973

Cmax(dn) is Cmax divided by dose.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · ng/mL/mg
Dose Normalized Cmax [Cmax(dn)] of IV and Oral GDC-0973
ng/mL/mgGDC-0973 2 mg IVGDC-0973 20 mg Oral
Dose Normalized Cmax [Cmax(dn)] of IV and Oral GDC-097310.2 ± 35.60.844 ± 26.4
Statistical analysis
  • GDC-0973 2 mg IV vs GDC-0973 20 mg Oral · Ratio of ls means: 8.45 · 90% CI 7.08 to 10.08The 90 percent (%) confidence intervals (CI) of test group (oral dose) means relative to reference group (IV dose) means were obtained by taking antilog of corresponding 90% CI for the differences between the means on the log scale.
PrimaryMinimum Observed Plasma Trough Concentration (Cmin) of IV and Oral GDC-0973
Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · ng/mL
Minimum Observed Plasma Trough Concentration (Cmin) of IV and Oral GDC-0973
ng/mLGDC-0973 2 mg IVGDC-0973 20 mg Oral
Minimum Observed Plasma Trough Concentration (Cmin) of IV and Oral GDC-09730.261 ± 37.10.546 ± 70.0
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of IV and Oral GDC-0973
Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax) of IV and Oral GDC-0973
hrGDC-0973 2 mg IVGDC-0973 20 mg Oral
Time to Reach Maximum Observed Plasma Concentration (Tmax) of IV and Oral GDC-09730.500 (0.500 to 0.567)4.00 (2.00 to 8.00)
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of IV and Oral GDC-0973

AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of IV and Oral GDC-0973
ng*hr/mLGDC-0973 2 mg IVGDC-0973 20 mg Oral
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of IV and Oral GDC-0973156 ± 19.1688 ± 28.4
PrimaryDose Normalized AUC (0-t) [AUC (0-t)dn] of IV and Oral GDC-0973

AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t). AUC (0-t)dn is AUC (0-t) divided by dose.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · ng*hr/mL/mg
Dose Normalized AUC (0-t) [AUC (0-t)dn] of IV and Oral GDC-0973
ng*hr/mL/mgGDC-0973 2 mg IVGDC-0973 20 mg Oral
Dose Normalized AUC (0-t) [AUC (0-t)dn] of IV and Oral GDC-097377.8 ± 19.138.2 ± 28.4
Statistical analysis
  • GDC-0973 2 mg IV vs GDC-0973 20 mg Oral · Ratio of ls means: 48.6 · 90% CI 41.43 to 56.94The 90% CI of the test group (oral dose) means relative to the reference group (IV dose) means were obtained by taking the antilog of the corresponding 90% CI for the differences between the means on the log scale.
PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of IV and Oral GDC-0973

AUC (0 - ∞)= Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of IV and Oral GDC-0973
ng*hr/mLGDC-0973 2 mg IVGDC-0973 20 mg Oral
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of IV and Oral GDC-0973188 ± 16.2784 ± 29.5
PrimaryDose Normalized AUC (0 - ∞) [AUC (0 - ∞)dn] of IV and Oral GDC-0973

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞)dn is AUC(0 - ∞) divided by dose.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · ng*hr/mL/mg
Dose Normalized AUC (0 - ∞) [AUC (0 - ∞)dn] of IV and Oral GDC-0973
ng*hr/mL/mgGDC-0973 2 mg IVGDC-0973 20 mg Oral
Dose Normalized AUC (0 - ∞) [AUC (0 - ∞)dn] of IV and Oral GDC-097393.9 ± 16.243.5 ± 29.5
Statistical analysis
  • GDC-0973 2 mg IV vs GDC-0973 20 mg Oral · Ratio of ls means: 45.9 · 90% CI 39.74 to 53.06The 90% CI of the test group (oral dose) means relative to the reference group (IV dose) means were obtained by taking the antilog of the corresponding 90% CI for the differences between the means on the log scale.
PrimaryPlasma Decay Half-Life (t1/2) of IV and Oral GDC-0973

t1/2 is the time measured for the plasma concentration of GDC-0973 to decrease by one half.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · hr
Plasma Decay Half-Life (t1/2) of IV and Oral GDC-0973
hrGDC-0973 2 mg IVGDC-0973 20 mg Oral
Plasma Decay Half-Life (t1/2) of IV and Oral GDC-097373.8 ± 17.166.2 ± 18.2
PrimarySystemic Clearance (CL) of IV GDC-0973

CL is a quantitative measure of the rate at which a drug substance is removed from the body.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · Liter (L)/hr
Systemic Clearance (CL) of IV GDC-0973
Liter (L)/hrGDC-0973 2 mg IV
Systemic Clearance (CL) of IV GDC-097310.7 ± 16.2
PrimaryApparent Oral Clearance (CL/F) of Oral GDC-0973

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modelling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · L/hr
Apparent Oral Clearance (CL/F) of Oral GDC-0973
L/hrGDC-0973 20 mg Oral
Apparent Oral Clearance (CL/F) of Oral GDC-097323.0 ± 29.5
PrimaryVolume of Distribution at Steady State (Vss) of IV GDC-0973

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vss is the apparent volume of distribution at steady-state.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose of Day 1
Reported as:
Geometric mean · Liter
Volume of Distribution at Steady State (Vss) of IV GDC-0973
LiterGDC-0973 2 mg IV
Volume of Distribution at Steady State (Vss) of IV GDC-09731052 ± 28.2
PrimaryApparent Volume of Distribution (Vz/F) of Oral GDC-0973

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F is influenced by the fraction absorbed.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) of Oral GDC-0973
LiterGDC-0973 20 mg Oral
Apparent Volume of Distribution (Vz/F) of Oral GDC-09732197 ± 31.9
PrimaryAbsolute Oral Bioavailability (F) of GDC-0973

Absolute oral bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose. F = \[AUC (0-∞), oral multiplied by Dose IV\] divided by \[AUC (0-∞), IV multiplied by Dose oral\]. Absolute oral bioavailability is determined for drugs which are administered orally. IV dose is 100% in systemic circulation (dosed directly) and hence no estimation is required.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · Ratio
Absolute Oral Bioavailability (F) of GDC-0973
RatioGDC-0973 20 mg Oral
Absolute Oral Bioavailability (F) of GDC-09730.457 ± 25.0
PrimaryMean Absorption Time (MAT)

MAT is mean time required for the drug to reach the central compartment. MAT was estimated from the mean resident time (MRT) from oral and IV administration. MAT was calculated as MRT last of oral dose minus MRT last of IV dose. MAT is analyzed when drug is administered orally (only for non-IV routes of administration).

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Reported as:
Geometric mean · hr
Mean Absorption Time (MAT)
hrGDC-0973 20 mg Oral
Mean Absorption Time (MAT)2.67 ± 58.0
PrimaryAmount of Drug Excreted in the Urine (Aeu) of IV and Oral GDC-0973

The cumulative amount of drug excreted in urine over the entire collection interval of 96 hrs was calculated by adding the Aeu of the intervals 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 hrs where Aeu was calculated by multiplying the urine volume within the collection interval by the associated drug concentration.

Time frame:
Part 2: 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 Hrs post-dose on Day 1
Reported as:
Geometric mean · mg
Amount of Drug Excreted in the Urine (Aeu) of IV and Oral GDC-0973
mgGDC-0973 2 mg IVGDC-0973 20 mg Oral
Amount of Drug Excreted in the Urine (Aeu) of IV and Oral GDC-09730.0761 ± 22.30.379 ± 33.9
PrimaryRenal Clearance (CLR) of IV and Oral GDC-0973

CLR was calculated as Aeu divided by AUC (0 - ∞), where Aeu was amount of drug excreted in urine from time 0 to 96 hrs post-dose and AUC(0 - ∞) was area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity hrs post-dose.

Time frame:
Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1 for plasma; 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 Hrs post-dose for urine
Reported as:
Geometric mean · L/hr
Renal Clearance (CLR) of IV and Oral GDC-0973
L/hrGDC-0973 2 mg IVGDC-0973 20 mg Oral
Renal Clearance (CLR) of IV and Oral GDC-09730.405 ± 20.10.484 ± 22.4
PrimaryPercent of GDC-0973 Excreted in the Urine (% Excreted) for IV and Oral GDC-0973

% Excreted is the mean percentage of dose recovery in urine and calculated as: (Aeu divided by dose) multiplied by 100, where Aeu was amount of drug excreted in urine from time 0 to 96 hrs post-dose.

Time frame:
Part 2: 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 Hrs post-dose
Reported as:
Geometric mean · Percent dose excreted
Percent of GDC-0973 Excreted in the Urine (% Excreted) for IV and Oral GDC-0973
Percent dose excretedGDC-0973 2 mg IVGDC-0973 20 mg Oral
Percent of GDC-0973 Excreted in the Urine (% Excreted) for IV and Oral GDC-09733.81 ± 22.31.90 ± 33.9

Adverse events

Collected over Adverse events were recorded from start of study treatment in first period to end of second period (up to 30 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GDC-0973 2 mg IV—0/13 (0%)2/13 (15.4%)
GDC-0973 20 mg Oral—0/12 (0%)3/12 (25%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventGDC-0973 2 mg IVGDC-0973 20 mg Oral
NauseaGastrointestinal disorders0/132/12
DizzinessNervous system disorders0/132/12
VomitingGastrointestinal disorders0/131/12
HeadacheNervous system disorders1/131/12
Loss of consciousnessNervous system disorders0/131/12
Feeling hotGeneral disorders0/131/12
ExcoriationInjury, poisoning and procedural complications0/131/12
Skin lacerationInjury, poisoning and procedural complications0/131/12
Neck painMusculoskeletal and connective tissue disorders0/131/12
HyperhidrosisSkin and subcutaneous tissue disorders0/131/12

Baseline characteristics

Safety population included participants who received study drug and had at least 1 post-dose safety assessment for Part 1 and the participants who were randomized, received study drug, and had at least 1 post-dose safety assessment for Part 2.

Age, Continuous
Age, Continuous(Years)Entire Study Population
Mean35 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female5
Male8
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 6 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2010
First posted
Nov 29, 2010
Start
Nov 2010
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
Feb 6, 2017
Last update
May 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01249118
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 29, 2010
Start date
Nov 2010
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Feb 6, 2017
Last update
May 10, 2017

Study contacts

Isabelle Rooney, M.D., PhD
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion